Skip to content
Wired News Engine – Lifestyle
Author:
Elixirgen Therapeutics, Inc.
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
June 26, 2026